Among last week's highlights, Keryx jumps on a solid Phase III trial, Sarepta gets pounded from a fake tweet and Halozyme suffers from analyst downgrades. More
-
Sponsored By:
-
Sponsored By:
-
Sponsored By:
Biotech Movers
See all posts in the Biotech topic.
Biotech Movers: Dendreon Pops, ArQule Drops
An analyst upgrade on DNDN lifted the shares 21% last Friday, but mid-stage trial failure of a colorectal drug sank ARQL 11% the same day. More
Biotech Movers: Ariad Sinks, YM Soars
They were among the sector's big newsmakers last week, with Acadia, Oncolytics and Acura Pharmaceuticals. More
Biotech Movers: A Tough Week All Around
Amarin Corp. slides on dashed buyout hopes, while Sarepta, Galena and others also faced serious setbacks. More
Biotech Movers: Acadia Rockets on Trial News
Acadia Pharmaceuticals leads the way with a week of eye-popping gains. Plus: Why Exelixis and Supernus took tough tumbles. More
Biotech Movers: Regeneron Pops, 3 Flop
While Regeneron soared on behind its macular degeneration treatment, Dynavax, Navidea and AspenBio suffered serious setbacks. More
4 Attractive Biopharma Stocks of All Sizes
Biopharma is a high-growth niche in a defensive sector, but you need to balance risk with reward. Here are four hot biopharma stocks of different sizes. More
Biotech Movers: Sequenom Soars on Blood Test Success
SONM sees significant gains despite a sub-par earnings report. Plus: Why Array and Vivus took big falls. More
Biotech Movers: Enzo Biochem Rockets on Patent Ruling
ENZ is awarded $48.6 million in penalties, and more could be coming. Plus: Why Abiomed, Pain Therapeutics, Impax and BioCryst all took big falls. More
